The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya.

Coronary Artery Disease Clinical Trial

— BSU  

Official title:

The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05531552
• Other study ID #: Clinical pharmacist role & ICU
• Status: Completed
• Start date: January 1, 2021
• Est. completion date: June 30, 2022

Study information

• Verified date: September 2022
• Source: Beni-Suef University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Assessment of role of clinical pharmacist in decreasing morbidity and mortality among coronary artery disease patients.

Description:

- Methodology: Follow-up patients from (A to Z) and their risk factors in all phases of disease (CAD) in groups with advised patients to lose weight, decrease smoking, and take medication on time. Monitoring drugs to CAD by studying its Pharmacodynamic: Mechanism of action, therapeutic uses [indication], adverse effect and suitable doses, and drug-drug interactions and contraindications * The study shows the Compare between the patients in (Medical Center Hospital) with and without guidelines of clinical pharmacy. Were managed all by setting a plan with the cardiologist in Libya. Follow-up was for the one hundred patients in the three groups {Outpatient, Inpatient, and the patients in Cardio Care Unit - CCU}. - First subgroup, Outpatient: monitored the drugs used in HTN, DM, and Hyperlipidemia (dyslipidemia) to decrease levels of patients who come to the hospital with IHD; therefore, reduce morbidity. Also, it was followed by measurement of BP twice weekly, test for Blood sugar (glucose level) once monthly, and tests the Low-Density Lipoprotein (LDL) at the cardiologist's request. - Second subgroup, Inpatient: monitored drugs according to international guidelines of clinical pharmacy to decrease the medication errors and management of the drug of stable angina and protected patients from increasing the problem, myocardial infarction, and reduce rates of entry to CCU. - Third subgroup, Patients in CCU: Practiced the international roles of clinical pharmacy to monitor drug use to unstable Angina and MI, to decrease mortality in Libya. - Method of analysis: Were monitored one hundred patients and divided into: • Twenty patients from (outpatient) divided to (10pts.-10pts.). (Ten patients) was written the data collected in accordance with the system adopted at the (Medical Center Hospital). (Ten patients)They are patients who applied the guidelines of clinical pharmacy to them in (Medical Center Hospital) by recommending cardiologists practice the clinical pharmacy guidelines and tailoring doses. - 50 of inpatients as outpatient (25pts.-25pts.). - 30 patients in CCU divided into (15pts.-15pts.). - The statistical analysis was the comparison between the two groups: - The first group of patients was undergoing treatment in the (Medical Center Hospital) without applying guidelines. (10 patients-25pts.-15pts.). - The second group; are a group of patients undergoing treatment in the (Medical Center Hospital) in accordance with guidelines. (10pts.-25pts.-15pts.). The comparison was in terms of the rate of survival, the speed of symmetry to heal ( i,e. responsiveness to medications), the rate of complications, and death for both groups. - The purpose of this review is to summarize the role of clinical pharmacy benefits in all aspects of cardiovascular diseases (CVD) in hospitalized patients. Managed the risk factors (hypertension, diabetes, dyslipidemia) and Ischemic heart disease by monitoring the common drugs in Libya: - Diuretics: ACEIs and ARBs for hypertension. - Insulin and Biguanides (Metformin) for diabetes. - Statins for dyslipidemia. - Organic nitrates: CCB, BB, Antiplatelets, Anticoagulant, and Fibrinolytics for ischemic heart disease. And the summary of the aim of the work is the practice of guidelines of clinical pharmacy to manage coronary artery disease to reduce levels of morbidity and mortality in Libya and to prove the need for the presence of clinical pharmacists in Libyan hospitals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 41 Years to 75 Years

Eligibility

Inclusion Criteria:

• The inclusion criteria were all adults =40 years of age, with a diagnosis of CAD.

Exclusion Criteria:

• exclusion criteria were patients with various comorbidities such as liver or kidney disease; patients intake alcohol, cardiac surgery and refusal to give informed consent.

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Drug:
• clinical pharmacy application
assessment clinical pharmacist in management of CAD and ICU patients.

Locations

Country	Name	City	State
Egypt	Beni-suef university	Bani Suwayf

Sponsors (3)

Lead Sponsor	Collaborator
Beni-Suef University	Cairo University, Medical Center Hospital, libya

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Angina pectoris.	Periodically data collected. [ex: the measurements of blood pressure, glucose blood serum, and LDL - (and taken the average during the period)]. The parameters in the research (angina, response to treatment, complication rate, and mortality) - were quantitatively collected, as the results added to the paper contain the number of patients with details of their complications or the cause of death of patients who died).; The measuring of FBG level (mg/dl), and (LDL-C) mg/dl - was then performed using a fully automated chemistry analysis instrument by Roche company (Cobas Integra 400 plus). And using specific kits for blood glucose levels (System ID 07-6831-6) and using kits for (LDL-C) (System ID 07-6726-3), Troponin (ng\ml) was performed by using (Beckman coulter - Access 2).; Angina pectoris was more predominant in patients in group (I); vs. in group (II) with a statistically significant difference.	18 months, from Jan 2021 to June 2022.
Primary	Responsiveness to medications.	Periodically data collected. [ex: the measurements of blood pressure, diabetes, lipid profile, and weight - (and taken the average during the period)]. The parameters in the research (angina, response to treatment, complication rate, and mortality) - were quantitatively collected, as the results added to the paper contain the number of patients with details of their complications or the cause of death of patients who died).; Follow-up patients, their clinical state and side effects of medications, Following the number of Hospitalization decreased.; Responsiveness to medications was significantly higher among patients from the group (II); compared with a control group (I)	18 months, from Jan 2021 to June 2022.
Primary	The incidence of complications.	The complications are noticeable: myocardial infarctions [Troponin was perpetrated by using by (Beckman coulter)(Access 2) ng\ml], cardiac arrhythmias [by ECG], cardiogenic shock [after MI with HF and low BP], HTN crisis {BP measure, DKA [high blood glucose with (+) positive Ketones.; Data were collected quantitatively, as the results added to the paper contain the number of patients with details of their complications).	18 months, from Jan 2021 to June 2022.
Primary	The mortality.	The causes of death are cardiogenic shock, ventricular tachycardia, and myocardial infarction.	18 months, from Jan 2021 to June 2022.